News

These continuing education activities are intended for hematologists, pediatricians, and other healthcare professionals who manage patients with hemophilia. The National Hemophilia Foundation…

NHF is excited to launch Run, White, & Blue for Bleeding Disorders – a family-friendly virtual event, featuring a 5K and Family Fun…

A paper published in the journal Haemophilia, suggests that clinical expectations for people with hemophilia have remained relatively static for years, falling out…

HFA is pleased to announce new dates for our previously-postponed Symposium. The 2020 Symposium will be held Aug. 24-29, 2020. HFA’s Symposium is an…

To all physicians, hematologists, and other healthcare professionals It has become apparent in the recent weeks that COVID-19 patients with severe disease…

Join the World Federation of Hemophilia (WFH) for a high-profile six-day virtual event, June 14-19, 2020: Connecting the Global Bleeding Disorders Community….

The National Hemophilia Foundation will be holding our quarterly Board of Directors meeting on Thursday, May 28th at 7:00 PM EDT. The Board…

Dear Community Members, The National Hemophilia Foundation wishes to inspire and partner with the community on their journeys to a cure and…

UniQure N.V., a gene therapy company advancing transformative therapies for patients with severe medical needs, reported recent progress across its business. “Despite…

Pfizer Inc. and BionTech SE announced the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for…

Findings from an international study published in the journal Medicine suggest that the visible presence of blood in urine (macroscopic hematuria) could represent increased…

Dear Community Members, The National Hemophilia Foundation’s priority has always been the health and safety of the bleeding disorders community. As the…

The National Hemophilia Foundation (NHF) and Hemophilia Federation of America (HFA) are seeking comments from the bleeding disorders community on the executive summary…

Genentech recently distributed a notice relevant to its product Hemlibra®, reminding health care providers that it is known to interfere with certain laboratory assays used to…

BD is conducting a voluntary medical device recall for multiple lots of the BD PosiFlush™ SF (Sterile Field) Saline Flush Syringe 10mL identified…

The Centers for Disease Control and Prevention (CDC) are currently soliciting written comments on pain and pain management, including those relevant to…

BD is conducting a voluntary medical device recall for multiple lots of the BD PosiFlush™ SF (Sterile Field) Saline Flush Syringe 10mL identified…

The National Hemophilia Foundation (NHF)  is seeking comments on draft ASH, ISTH, NHF and WHF clinical practice guidelines on VWD Diagnosis &…

The National Hemophilia Foundation’s (NHF’s) Medical and Scientific Advisory Council (MASAC) issued four new documents, which were adopted by NHF’s Board of…

Novo Nordisk recently announced that they have “paused” three clinical trials for their investigational subcutaneous therapy concizumab. The therapy is developed using…

As previously reported by HFA and NHF, Takeda announced the recall of two lots of VONVENDI von Willebrand factor (recombinant) 1,300 I.U….

Aptevo Theraoeutics has sold their recombinant factor IX product IXINITY® to Canada-based Medexus Pharmaceuticals. IXINITY®, which first received approval from the U.S….

The Partners in Bleeding Disorders Education Program has announced the launch a new version of “Understanding Hemophilia,” a six-part online learning activity for clinicians…

It is critical that an individual with a bleeding disorder who presents in an emergency department (ED) be triaged and administered care…